In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA. The decision gives the Danish company a voice in the case which surrounds the validity of its claim that it can meet the skyrocketing demand for its semaglutide products.
A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA. The decision gives the Danish company a voice in the case which surrounds the validity of its claim that it can meet the skyrocketing demand for its semaglutide products.
